(PBYI) Puma Biotechnology, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PBYI) Puma Biotechnology, Inc. Complete Analysis Pack
Puma Biotechnology’s Business Model, Simplified
Unlock the strategic blueprint behind Puma Biotechnology, Inc.’s business model. This concise Business Model Canvas shows how the company creates value, reaches customers, and supports growth in a competitive biotech market. Get the full version for deeper insights, clearer strategy, and a ready-to-use format for analysis or planning.
Partnerships
Pfizer, Inc. neratinib license
Pfizer, Inc. licensed neratinib to Puma Biotechnology, Inc. in 2011, making this the core origin partnership for PB272 and the basis for Puma’s rights to develop, market, and sublicense the asset. Puma still depends on licensed rights, not fully owned originator IP, so the agreement underpins the whole NERLYNX franchise and its downstream economics.
6 regional sublicense partners
Puma Biotechnology, Inc. uses 6 regional sublicense partners as its territory-based commercialization network: Specialised Therapeutics Asia, CANbridge BIOMED, Pint Pharma International, Knight Therapeutics, Pierre Fabre Medicament, and Bixink Therapeutics. This lets Puma extend reach beyond its direct operating footprint into Asia-Pacific, Greater China, Latin America, Canada, and Europe.
Oncology physicians and cancer centers
Oncology physicians and cancer centers are Puma Biotechnology, Inc.’s core clinical adoption partners, since neratinib is prescribed for HER2-driven breast cancer and HER2-mutant solid tumors. HER2 mutations appear in about 2% to 4% of breast cancers, and cancer centers help find eligible patients, start treatment, and manage oral dosing and side effects.
Manufacturing and supply vendors
Puma Biotechnology, Inc. relies on manufacturing and supply vendors to make NERLYNX, package oral doses, and move finished stock into commercial channels. With one marketed oral therapy and about $174.3 million in 2025 net sales, these partners help Puma keep product available without owning large factories.
Oral drug production support
Packaging and label services
Distribution for global supply
Critical for a small biopharma model
Regulatory and market access stakeholders
Regulatory and market access stakeholders shape Puma Biotechnology, Inc.’s path from FDA label to paid prescriptions, especially for NERLYNX in HER2-positive breast cancer. In 2025/2026, this matters because oncology access still depends on health authority review, payer coverage, and formulary placement before revenue turns on.
- FDA and other regulators set label scope.
- Payers decide reimbursement and patient access.
- Guidelines support coverage and uptake.
Puma’s Partnership Network Powers NERLYNX Sales
Puma Biotechnology, Inc.’s key partnerships center on Pfizer, Inc. for licensed neratinib rights, plus six regional sublicensees that extend NERLYNX reach across Asia-Pacific, Greater China, Latin America, Canada, and Europe. In 2025, NERLYNX net sales were $174.3 million, so these partners remain essential to access, revenue, and supply.
| Partner | Role | 2025/2026 relevance |
|---|---|---|
| Pfizer, Inc. | Origin license | Basis for neratinib rights |
| 6 sublicensees | Regional sales | Global territory coverage |
| Manufacturers | Supply chain | Support $174.3M sales |
What is included in the product
Detailed Word Document
A concise, real-world Business Model Canvas for Puma Biotechnology’s oncology-focused strategy, covering the 9 core blocks with investor-ready clarity.
Customizable Excel Spreadsheet
Quickly map Puma Biotechnology’s business model to spot and solve key pain points at a glance.
Reference Sources
Provides a concise source trail for Puma Biotechnology, Inc., helping decision-makers verify claims fast and trust the analysis.
Activities
PB272 clinical development
PB272 clinical development is Puma Biotechnology, Inc.'s core R and D engine: it keeps oral neratinib moving through studies in early-stage HER2-overexpressed or amplified breast cancer, advanced or metastatic HER2-positive breast cancer with capecitabine, and HER2-mutant solid tumors. These programs sit behind the Company Name's main value driver, with neratinib already anchored by approved use in HER2-positive breast cancer.
Regulatory submissions and safety monitoring
Puma Biotechnology, Inc. keeps regulatory submissions current by preparing filings, label updates, and compliance work for Nerlynx, its breast cancer therapy sold in the U.S. and abroad in 2025. Pharmacovigilance is core because broad use across treatment settings means every adverse-event report can affect patient safety and market access.
Commercialization of neratinib
Puma Biotechnology, Inc. turns neratinib into sales through direct U.S. commercialization and partner-led launches in licensed markets, with market planning, payer access, and HCP promotion built around NERLYNX. In 2024, the Company reported net product revenue of about $184 million, showing it is a commercialization-focused biopharma, not just a developer.
Alliance and sublicense management
Alliance and sublicense management means Puma Biotechnology, Inc. actively oversees neratinib’s licensing network, checking partner performance, territory rights, and contract terms. This keeps execution tight across the Pfizer-originated asset and supports consistent global commercialization.
It also helps Puma track royalties, compliance, and milestone duties across each sublicense.
- Monitor partner delivery
- Protect territory rights
- Enforce contract terms
- Align global neratinib execution
Supply chain and lifecycle oversight
Puma Biotechnology, Inc. keeps tight control of NERLYNX inventory, product flow, and label updates so supply stays steady across U.S. direct sales and partner markets. With a single oral oncology product, planning for launches, safety changes, and cross-market supply is critical to protect revenue and access.
- Track inventory and expiry
- Align supply with demand
- Manage label and lifecycle updates
- Support direct and partner sales
Puma Biotech: Nerlynx Drives $184M Revenue, PB272 in Focus
Puma Biotechnology, Inc. focuses on three key activities: advancing PB272 clinical trials, running Nerlynx regulatory and safety work, and managing U.S. and partner-market commercialization. In 2025, the Company kept its single-product model centered on oral neratinib, with 2024 net product revenue of about $184 million showing the scale of execution.
| Key activity | Latest data |
|---|---|
| Net product revenue | About $184 million |
| Core asset | Nerlynx |
| Pipeline focus | PB272 trials |
Delivered as Displayed
Business Model Canvas
The Puma Biotechnology, Inc. Business Model Canvas preview you see here is the exact document you’ll receive after purchase. It is not a sample or mockup, but a direct view of the final file. Once your order is complete, you’ll get the same professionally formatted content, ready to use, edit, or present.
Resources
Neratinib rights from Pfizer
Neratinib rights from Pfizer are Puma Biotechnology, Inc.’s core strategic asset: they are the licensed IP behind Nerlynx, the company’s only marketed product, and without them Puma would not have its current development or commercialization model. In 2025, that asset still anchored all product sales and cash flow, with Puma continuing to rely on the Pfizer license to defend and extend value.
Oral PB272 oncology asset
Puma Biotechnology, Inc.'s oral PB272 oncology asset is its lead drug candidate and the core of its commercial platform. The oral format is part of the product’s identity, and the asset supports multiple HER2-driven cancer opportunities, a market segment that still drives a large share of targeted oncology spending.
6 sublicensing agreements
As of FY2025, Puma Biotechnology uses 6 sublicensing agreements to extend market access across geographies, so it can reach more patients without building a large global sales force. This partner network can also produce royalty and milestone income, which helps support a leaner operating model.
Clinical and regulatory data package
Clinical and regulatory data package is Puma Biotechnology, Inc.'s core evidence base for NERLYNX, linking trial and post-marketing outcomes to specific breast cancer uses. It supports FDA label maintenance, payer confidence, and physician adoption, which matters most in oncology because outcomes data drives uptake.
- Approval support
- Label maintenance
- Physician adoption
Los Angeles headquarters and team
Puma Biotechnology, Inc., founded in 2010, is headquartered in Los Angeles, California. That Los Angeles base is the company’s operating hub, supporting corporate, scientific, and partner-management work.
- Los Angeles, California headquarters
- Founded in 2010
- Runs corporate and scientific functions
- Supports partner management
Puma’s Core Edge: Neratinib IP and 6 Sublicensing Deals
Key Resources at Puma Biotechnology, Inc. are led by the Pfizer-licensed neratinib IP behind NERLYNX, plus the clinical and regulatory data package that keeps the label, payer access, and physician use in place. In FY2025, 6 sublicensing agreements also mattered as a lean way to extend reach and support royalties without a large global sales build.
| Key Resource | FY2025 signal |
|---|---|
| Neratinib license | Core product rights |
| Sublicensing network | 6 agreements |
| Data package | Supports approval and adoption |
Value Propositions
Oral HER2-targeted therapy
Puma Biotechnology, Inc. offers NERLYNX, an oral HER2-targeted therapy for HER2-driven breast cancer, a group that makes up about 15% to 20% of breast cancers. Oral dosing can let patients treat at home instead of coming in for infusion, which is a clear day-to-day advantage for both clinicians and patients.
Early-stage HER2 breast cancer option
Neratinib gives Puma Biotechnology, Inc. a targeted option for patients with early-stage HER2-overexpressed or amplified breast cancer after standard therapy. In ExteNET, 2,840 patients were studied, and the 5-year invasive disease-free survival rate was 90.2% versus 87.7% with placebo, supporting value in a defined high-need oncology group.
Metastatic HER2-positive combination use
Puma Biotechnology, Inc.’s metastatic HER2-positive use centers on adult patients with advanced or metastatic HER2-positive breast cancer treated with capecitabine, a later-line setting that widens the addressable population. HER2-positive disease is about 15% to 20% of breast cancers, so pairing with capecitabine supports real commercial relevance where treatment options are already limited.
HER2-mutant solid tumor potential
Puma Biotechnology, Inc.'s HER2-mutant solid tumor work extends neratinib beyond breast cancer, widening the addressable oncology pool. HER2 mutations appear in about 2%-4% of non-small cell lung cancer and in smaller subsets of other solid tumors, so one molecule can support pipeline optionality across multiple indications.
- Broader than breast cancer
- Targets HER2-mutant tumors
- Creates one-molecule optionality
Global development through partners
Puma Biotechnology, Inc. uses licensing and sublicensing to push its products into multiple territories without building a large sales force in every country. That partner-led model keeps the internal team lean while still giving Puma a broad global footprint through local commercial partners.
- Licensing expands territory reach fast
- Sublicensing adds local market access
- Less direct infrastructure, lower fixed cost
- Focused team can stay small and sharp
Puma’s Oral HER2 Therapy Shows Clear Niche Value
Puma Biotechnology, Inc. sells NERLYNX as an oral, at-home HER2 therapy for early-stage and metastatic breast cancer, plus HER2-mutant solid tumors. In ExteNET, 2,840 patients saw 5-year invasive disease-free survival of 90.2% versus 87.7% with placebo, showing a clear niche value.
| Value | Proof |
|---|---|
| Oral HER2 treatment | Home use, no infusion |
| Early breast cancer | ExteNET: 90.2% vs 87.7% |
| Broader reach | HER2-mutant solid tumors |
Customer Relationships
Oncologist-led prescription support
Oncologist-led prescription support means oncologists decide when and how neratinib fits the treatment pathway, so Puma Biotechnology, Inc. must win on evidence, not sales pressure. In ExteNET, 5-year invasive disease-free survival was 90.2% with neratinib vs 87.7% with placebo, so medical information has to help doctors prescribe with confidence.
Medical affairs education
Medical affairs education at Puma Biotechnology, Inc. centers on scientific exchange, product information, and disease education for oncology specialists, so adoption depends on peer-level evidence, not consumer marketing. This expert-led model helps clinicians use therapies appropriately and align care with the latest clinical data.
Partner account management
Puma Biotechnology, Inc. uses partner account management to keep close control over sublicensees and commercial partners, with regular reviews of forecasts, sales performance, and contract duties. This long-term B2B model matters because the company’s success depends on tight coordination, clear accountability, and steady execution across partner channels.
Pharmacovigilance reporting
Pharmacovigilance reporting keeps Puma Biotechnology, Inc. in steady safety contact with oncologists, hospitals, and regulators, so adverse events and product-quality issues are tracked fast and shared clearly. In cancer care, this protects trust and supports compliance across every safety report, signal review, and follow-up case.
- Continuous adverse-event monitoring
- Regulator-ready safety reporting
- Protects trust and compliance
Access and reimbursement coordination
Puma Biotechnology’s access and reimbursement work has to focus on payers, hospitals, and institutions because oncology treatment often depends on formulary status and reimbursement approval. With just 1 marketed oncology product, NERLYNX, Puma Biotechnology must support both product availability and real clinical use through coverage navigation.
That means helping providers document medical need, align with payer rules, and reduce delays that can block therapy starts. In practice, reimbursement support is a key part of getting patients from prescription to treatment.
- Engage payers on formulary access
- Support hospital reimbursement pathways
- Help institutions document clinical need
Puma Biotech: Oncologist trust and payer access drive NERLYNX growth
Puma Biotechnology, Inc. keeps customer ties through oncologist education, safety follow-up, and reimbursement support, because NERLYNX use depends on specialist trust and payer access. Its evidence base matters: ExteNET showed 5-year invasive disease-free survival of 90.2% vs 87.7% with placebo.
| Channel | Key fact |
|---|---|
| Medical affairs | Oncologist-led evidence exchange |
| Access support | 1 marketed oncology product |
Channels
Hospital oncology clinics
Hospital oncology clinics are the main point for prescribing and starting therapy for HER2-driven cancers; about 15% to 20% of breast cancers are HER2-positive, so treatment is usually led by oncologists and specialist teams. This channel puts Puma Biotechnology, Inc.'s therapy in front of the doctors who choose and monitor treatment, especially after prior HER2-directed care.
Specialty pharmacy distribution
Puma Biotechnology, Inc. uses specialty pharmacy channels for its oral oncology medicine, mainly NERLYNX, to control dispensing, manage prior authorization, and support patients with refill reminders and side-effect help. This channel improves adherence and gives Puma tighter supply visibility, which matters for an oral drug sold through restricted specialty distribution.
Regional sublicense partner sales forces
Puma Biotechnology, Inc. uses regional sublicense partner sales forces to tap local commercial teams that know each market, run promotion, and cover prescribers and hospitals. This channel is key to international reach because Puma avoids building its own field force in every country and lets partners handle local access, language, and reimbursement rules.
Medical conferences and scientific exchange
Medical conferences and scientific exchange are a key evidence-sharing channel for Puma Biotechnology, Inc. with oncology experts. In biopharma, conference presence helps explain clinical data, safety, and treatment positioning, and scientific credibility can support prescription uptake and payer trust.
- Reach oncology KOLs directly
- Share trial data fast
- Support treatment positioning
Digital medical and partner communications
Puma Biotechnology, Inc. uses online product pages, partner portals, and corporate releases to push physician and alliance updates fast across markets. In 2025, this digital layer supported Nerlynx communication for a global commercial base, helping one message reach clinicians and partners at the same time.
- Online product data for physicians
- Partner portals for alliance access
- Corporate news for fast market updates
Puma’s Specialist-Driven NERLYNX Distribution Network
Puma Biotechnology, Inc.'s channels are built around oncology specialists, specialty pharmacy, partner sales forces, and scientific forums, with NERLYNX mainly reaching prescribers through controlled specialty distribution. HER2-positive breast cancer accounts for about 15% to 20% of cases, so these channels target high-value, specialist-led treatment points.
| Channel | Role |
|---|---|
| Specialty pharmacy | Dispense NERLYNX |
| Partner sales forces | Local market access |
Customer Segments
Early-stage HER2 breast cancer patients
Patients with early-stage HER2-overexpressed or amplified breast cancer are a core customer segment for Puma Biotechnology, Inc., because the Company’s lead asset is used in this exact setting. HER2-positive disease makes up about 15% to 20% of breast cancers, so this group is large enough to drive meaningful prescribing while matching Puma’s stated indication focus.
Advanced HER2-positive breast cancer patients
Advanced HER2-positive breast cancer patients are adults with unresectable or metastatic disease who receive capecitabine-based later-line therapy, including Puma Biotechnology, Inc.’s neratinib combination use. This is a core commercial segment: HER2-positive breast cancer accounts for about 15% to 20% of breast cancer cases, and metastatic disease drives high-value oncology demand.
HER2-mutant solid tumor patients
HER2-mutant solid tumor patients include people with HER2 mutations in cancers beyond breast, such as non-small cell lung, colorectal, and bladder cancer. In non-small cell lung cancer, HER2 mutations are found in about 2% to 4% of cases, making this a real but still under-served niche for Company Name’s exploratory growth base.
Oncologists and cancer centers
Oncologists and cancer centers are Puma Biotechnology, Inc.'s core decision-makers: they diagnose, prescribe, and monitor therapy for HER2-positive breast cancer. In 2025, this matters because treatment choice is driven by clinical fit, safety, and adherence, with specialist uptake shaping Nerlynx use in real practice.
- Diagnose and stage patients
- Prescribe and monitor therapy
- Drive adoption in cancer centers
- Focus on efficacy and safety
Regional pharmaceutical partners
Regional pharmaceutical partners are the ex-U.S. sublicensees that commercialize neratinib in their own territories, letting Puma Biotechnology, Inc. reach more markets without building a full local sales force. This channel mix supports global scale with local execution and keeps regional compliance, pricing, and access decisions closer to each market.
- Ex-U.S. sublicensees sell neratinib locally
- Expands reach beyond direct channels
- Supports scale with local market execution
HER2: A Focused Market Across Patients, Doctors, and Pharma Partners
Company Name serves four buyers: HER2-positive breast cancer patients, HER2-mutant solid tumor patients, oncologists, and ex-U.S. pharma partners. HER2-positive breast cancer is about 15% to 20% of breast cancers, while HER2 mutations are about 2% to 4% of NSCLC cases.
| Segment | Key fact |
|---|---|
| Patients | 15% to 20% HER2+ |
| NSCLC niche | 2% to 4% HER2-mutant |
| Doctors | Prescribe and monitor |
Cost Structure
R and D and clinical trials
R and D and clinical trials are Puma Biotechnology, Inc.'s main scientific cost base. Multi-indication HER2 programs need protocol design, site operations, patient monitoring, and data analysis, and in biopharma this is usually the largest expense line. In Puma Biotechnology, Inc., this spend stays tied to trial progress and regulatory milestones.
Royalty obligations to Pfizer
Puma Biotechnology’s neratinib sales still carry Pfizer royalty obligations from the original license, so this is a recurring cost tied directly to the origin asset. In 2025, that meant a variable expense on every dollar of product revenue, not a one-time fee, and it remains a fixed item in the cost base as long as Puma uses Pfizer’s intellectual property.
Sales, marketing, and medical affairs
Puma Biotechnology's sales, marketing, and medical affairs costs fund commercialization, physician education, and field support; in 2025, selling, general and administrative expense was about $52 million, showing the size of the push needed to drive uptake.
Even with partners, Puma still has to pay for product awareness and scientific communication so trial evidence turns into prescriptions, not just publications.
General and administrative overhead
Puma Biotechnology, Inc.'s general and administrative overhead sits in its Los Angeles headquarters and covers executive, finance, legal, and corporate support teams. Even as a lean biopharma, these are fixed costs that keep compliance, reporting, and day-to-day control running.
- Los Angeles HQ functions
- Executive, finance, legal
- Fixed biopharma operating cost
Manufacturing, compliance, and safety oversight
Manufacturing, compliance, and safety oversight are a core cost for Puma Biotechnology, Inc. because oncology products need strict supply chain control, quality checks, and pharmacovigilance to track adverse events after launch. These controls support global commercialization and, in 2025, they remained tied to regulatory filing, batch release, and post-market monitoring costs.
- Supply chain control and supplier audits
- Quality testing and batch release
- Pharmacovigilance and safety reporting
- Regulatory and post-market oversight
Puma’s 2025 Costs: R&D Heavy, SG&A at $52M
Puma Biotechnology, Inc.'s cost structure in 2025 was dominated by R&D, with selling, general and administrative expense at about $52 million. Neratinib commercialization also carried Pfizer royalty costs, while manufacturing, quality, and safety oversight stayed fixed around supply chain control and pharmacovigilance.
| Cost item | 2025 data |
|---|---|
| SG&A | ~$52 million |
| Royalty burden | Variable on neratinib sales |
| R&D | Trial-driven major cost base |
Revenue Streams
Neratinib product sales
Neratinib product sales are Puma Biotechnology, Inc.'s direct commercialization revenue from the oral oncology asset, and they remain the main way the company monetizes its breast cancer and other solid tumor use cases. In fiscal 2025, this stream still anchored Puma Biotechnology, Inc.'s top line and reflected real-world demand for the therapy.
Sublicense royalty income
Puma Biotechnology, Inc. earns sublicense royalty income from regional partners, adding an international layer to revenue beyond direct product sales. The company has six named sublicensees, so this partner-led model helps spread geographic reach while keeping fixed selling costs low.
In the latest filings, this stream remains a recurring but smaller income source than product sales, yet it is strategically important because each royalty payment ties outside partners to the same asset base.
Milestone payments from partners
Puma Biotechnology, Inc. can earn milestone payments when partners hit development, approval, or commercial targets. In biopharma licensing deals, these fees often arrive before full sales ramp, so they help turn progress into cash early.
This stream matters because milestone income can reduce reliance on product sales alone and smooth funding for later-stage programs. For Puma Biotechnology, Inc., that means partner-triggered cash can monetize pipeline progress before market maturity.
License fee income
License fee income at Puma Biotechnology, Inc. comes from upfront or ongoing partner payments tied to collaboration deals, including regional commercialization rights. This adds non-product revenue to the model, so cash can come in even when sales are driven by one core product.
Upfront fees from partnership signings
Ongoing fees tied to regional rights
Supports non-product revenue
Other collaboration revenue
Puma Biotechnology, Inc. also earns "other collaboration revenue" from partner-linked neratinib agreements, mainly contract receipts that are not direct product sales. This stream is usually small versus net product sales, but it helps fund operations and shows the company’s dependence on collaboration cash to support the neratinib network.
- Partner receipts, not product sales
- Tied to neratinib collaboration deals
- Supports operating cash generation
Puma Biotechnology Leans on Neratinib, With Partner Income as Backup
In fiscal 2025, Puma Biotechnology, Inc. stayed highly concentrated in neratinib net product sales, while six sublicensees added smaller but recurring royalty, milestone, license fee, and other collaboration income. This mix keeps cash tied to one core asset, with partner payments as a useful cushion.
| Stream | FY2025 role | Key fact |
|---|---|---|
| Neratinib sales | Main revenue | Core direct sales |
| Sublicense royalties | Recurring minor revenue | 6 sublicensees |
| Milestones, fees, collaboration revenue | Supplemental revenue | Partner-linked cash |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.